Macrophages in health and disease

Cell, Год журнала: 2022, Номер 185(23), С. 4259 - 4279

Опубликована: Ноя. 1, 2022

Язык: Английский

---

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Янв. 30, 2023

In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This consists of genetically engineered immune cells expressing surface receptor, called CAR, that specifically targets antigens expressed on tumor cells. hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, adoptive CAR-T shown efficacy in treating chemotherapy refractory patients. However, value this remains inconclusive context solid tumors is restrained by several obstacles including limited trafficking infiltration, presence an immunosuppressive microenvironment, well adverse events associated with such therapy. Recently, CAR-Natural Killer (CAR-NK) CAR-macrophages (CAR-M) were introduced complement/alternative for tumors. CAR-NK could be favorable substitute since they do not require HLA compatibility have toxicity. Additionally, might generated large scale from sources which would suggest them off-the-shelf product. CAR-M immunotherapy its capabilities phagocytosis, tumor-antigen presentation, broad currently being investigated. Here, we discuss emerging role CAR-T, CAR-NK, We also highlight advantages drawbacks compared Finally, prospective solutions potential combination therapies enhance CAR-cells immunotherapy.

Язык: Английский

---

A timeline of tumour-associated macrophage biology

Nature reviews. Cancer, Год журнала: 2023, Номер 23(4), С. 238 - 257

Опубликована: Фев. 15, 2023

Язык: Английский

---

Tumor‐associated macrophages in liver cancer: From mechanisms to therapy

Cancer Communications, Год журнала: 2022, Номер 42(11), С. 1112 - 1140

Опубликована: Сен. 7, 2022

Abstract Multidimensional analyses have demonstrated the presence of a unique tumor microenvironment (TME) in liver cancer. Tumor‐associated macrophages (TAMs) are among most abundant immune cells infiltrating TME and present at all stages cancer progression, targeting TAMs has become one favored immunotherapy strategies. In addition, distinct origins. At early stage cancer, can provide niche for maintenance stem cells. contrast, (CSCs) or poorly differentiated key factors modulating macrophage activation. review, we first propose origin connection between precursor Macrophages undergo dynamic phenotypic transition during carcinogenesis. this course such transition, it is critical to determine appropriate timing therapy block specific markers suppress pro‐tumoral TAMs. The review provides more detailed discussion trends surface than previous reviews. Complex crosstalk occurs play indispensable roles angiogenesis, autophagy due their heterogeneity robust plasticity. interact with other by directing cell‐to‐cell contact secreting various effector molecules. Similarly, combined drive recruitment polarization. Despite latest achievements advancements treatment strategies following studies, comprehensive discussions on communication currently lacking. discussed interactions (from cell maturation), therapeutic (including chimeric antigen receptor macrophages), clinical trials hepatocellular carcinoma (HCC) intrahepatic cholangiocarcinoma (iCCA) rationale further investigation as potential target treating patients

Язык: Английский

---

The biology of TREM receptors

Nature reviews. Immunology, Год журнала: 2023, Номер 23(9), С. 580 - 594

Опубликована: Фев. 7, 2023

Язык: Английский

---

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Март 21, 2023

Abstract In recent years, tumor immunotherapy has made significant progress. However, immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of patients in solid cancers. The microenvironment (TME) acts role immunotherapy. Studies reported that tumor-associated macrophages (TAMs), as one the main components TME, seriously affected therapeutic effect inhibitors. this review, we analyzed TAMs from epigenetic and single-cell perspectives introduced mechanisms anti-programmed death protein 1(anti-PD-1) therapy. addition, summarized combination regimens enhance efficacy elaborated on different Eventually, clinical value by influencing was discussed. These above are beneficial to elucidate poor tumors point view explore strategies improve its objective remission rate

Язык: Английский

---

IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer

Nature, Год журнала: 2023, Номер 623(7986), С. 415 - 422

Опубликована: Ноя. 1, 2023

Язык: Английский

---

Roles of macrophages in tumor development: a spatiotemporal perspective

Cellular and Molecular Immunology, Год журнала: 2023, Номер 20(9), С. 983 - 992

Опубликована: Июль 10, 2023

Abstract Macrophages are critical regulators of tissue homeostasis but also abundant in the tumor microenvironment (TME). In both primary tumors and metastases, such tumor-associated macrophages (TAMs) seem to support development. While we know that TAMs dominant immune cells TME, their vast heterogeneity associated functions only just being unraveled. this review, outline various known TAM populations found thus far delineate specialized roles with main stages cancer progression. We discuss how may prime premetastatic niche enable growth a metastasis then subsequent metastasis-associated can secondary growth. Finally, speculate on challenges remain be overcome research.

Язык: Английский

---

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes

Cancer Discovery, Год журнала: 2022, Номер 13(1), С. 23 - 40

Опубликована: Дек. 6, 2022

Breast cancer, the most common type of cancer affecting women, encompasses a collection histologic (mainly ductal and lobular) molecular subtypes exhibiting diverse clinical presentation, disease trajectories, treatment options, outcomes. Immunotherapy has revolutionized for some solid tumors but shown limited promise breast cancers. In this review, we summarize recent advances in our understanding complex interactions between tumor immune cells at cellular microenvironmental levels. We aim to provide perspective on opportunities future immunotherapy agents tailored specific features each subtype cancer. Although there are currently over 200 ongoing trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these largely restricted triple-negative HER2+ primarily focus T cells. With rapid expansion new vitro, vivo, data, it is critical identify highlight challenges unique drive next generation treatments that harness system.

Язык: Английский

---

High-resolution alignment of single-cell and spatial transcriptomes with CytoSPACE

Nature Biotechnology, Год журнала: 2023, Номер 41(11), С. 1543 - 1548

Опубликована: Март 6, 2023

Abstract Recent studies have emphasized the importance of single-cell spatial biology, yet available assays for transcriptomics limited gene recovery or low resolution. Here we introduce CytoSPACE, an optimization method mapping individual cells from a RNA sequencing atlas to expression profiles. Across diverse platforms and tissue types, show that CytoSPACE outperforms previous methods with respect noise tolerance accuracy, enabling cartography at

Язык: Английский

---